Arman Faravardeh is a Nephrology physician affiliated with Sharp HealthCare Foundation. OpenAlex indexes 10 publications with 327 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8010 Frost St Ste 100
San Diego, CA 921234222
Telephone
858-637-4700Provider last certified this registry record 2 Feb 2026.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Veloxis Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
37.8%Calcium channel blocker11.1%Nifedipine Er54%Amlodipine Besylate46%Part D≥22 patientsBeta blocker8.9%Carvedilol48%Metoprolol Tartrate37%Labetalol Hcl15%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
30.4%Corticosteroid18.1%Prednisone100%Part D≥65 patientsH2 blocker5.6%Famotidine100%Part D≥19 patients+ 3 more classes in this area
Other
9.5%Drugs for treatment of hyperkalemia and hyperphosphatemia5.2%Velphoro81%Lokelma19%Part D<11 patientsPhosphate Binder4.4%Sevelamer Carbonate100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Posoleucel in Kidney Transplant Recipients with BK Viremia
Journal of the American Society of Nephrology
2024 - The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: Results from a randomized phase 3 trial
American Journal of Transplantation
2024 - The failing kidney allograft: A review and recommendations for the care and management of a complex group of patients
American Journal of Transplantation
2021
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”